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ABSTRACT 
Previous studies have suggested that CD133+ cells isolated from human kidney biopsies have 
the potential to ameliorate injury following intravenous (IV) administration in rodent models 
of kidney disease by integrating into damaged renal tissue and generating specialised renal 
cells.  However, whether renal engraftment of CD133+ cells is a prerequisite for ameliorating 
injury has not yet been unequivocally resolved. Here, we have established a cisplatin-induced 
nephropathy model in immunodeficient rats to assess the efficacy of CD133+ human kidney 
cells in restoring renal health, and to determine the fate of these cells after systemic 
administration. Specifically, following IV administration, we evaluated the impact of the 
CD133+ cells on renal function by undertaking longitudinal measurements of the glomerular 
filtration rate using a novel transcutaneous device. Using histological assays, we assessed 
whether the human kidney cells could promote renal regeneration, and if this was related to 
their ability to integrate into the damaged kidneys. Our results show that both CD133+ and 
CD133- cells improve renal function and promote renal regeneration to a similar degree. 
However, this was not associated with engraftment of the cells into the kidneys. Instead, after 
IV administration, both cell types were exclusively located in the lungs, and had disappeared 
by 24 hours. Our data therefore indicate that renal repair is not mediated by CD133+ cells 
homing to the kidneys and generating specialised renal cells. Instead, renal repair is likely to 
be mediated by paracrine or endocrine factors.  
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INTRODUCTION   
Acute kidney injury (AKI) is associated with an abrupt decline in renal function, and is 
reported to have a mortality rate ranging from 18% to 80%1,2. The severity and duration of the 
acute injury correlates with the incidence of progression to chronic or even end stage renal 
disease (ESRD)3. Successful therapeutic interventions of AKI may not only promote recovery 
from acute injury, but could also decrease the incidence of ESRD.  
Cisplatin is a chemotherapy drug that is used to treat a wide range of solid  tumours4, but can 
cause severe nephrotoxicity, which is associated with 20-40% reduction in the glomerular 
filtration rate (GFR), increased serum urea, elevated serum creatinine (sCr) and acute tubular 
necrosis5,6.  
In rodent models, cisplatin-induced AKI is routinely used to test the efficacy of novel 
therapies7-11, including a range of cell-based regenerative medicine therapies12. Studies which 
tested the efficacy of mesenchymal stem/stromal cells (MSCs) showed that these cells 
promote repair through the secretion of paracrine factors that stimulate the regeneration of 
host renal tissue12-14. In contrast, nephron progenitor cells derived from human fetal kidneys 
appear to improve renal health by integrating into damaged rodent kidneys and generating 
specialised renal cells15.  
Recently, a population of putative progenitor cells expressing the glycosylated isoform of 
CD133 (Prominin-1) was identified in human adult kidneys16,17. CD133 is a marker of cancer 
stem cells and has been used to isolate stem and progenitor cells from several tissues18. 
Human adult kidney-derived CD133+ cells have been shown to ameliorate injury following 
intravenous (IV) administration in mouse models of glycerol-induced rhabdomyolysis16,19,20 
and adriamycin-induced nephropathy17. Specifically, it was suggested that CD133+ cells 
ameliorate injury by engrafting into the kidneys and differentiating into specialised renal 
cells17,19. These observations have raised the prospect of developing autologous cell therapies 
to replace damaged renal tissue in patients with kidney disease. 
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In order to track the fate of exogenous cells in preclinical models, cells are frequently labelled 
using membrane-bound dyes in order to allow their detection in histological sections at the 
study end point17,19,21. In previous studies assessing the role of CD133+ kidney-derived cells 
in ameliorating renal injury, cells labelled with the lipophilic fluorescent dye, PKH26, 
appeared to engraft in the kidney following IV administration and express markers of  
podocytes and proximal tubule cells (PTCs)17,19,21. However, PKH26 has been shown to be an 
unreliable tracking agent because it can be transferred to host cells, leading to false positive 
results22,23.  
In this study, we aimed to accurately assess the improvement of renal function in response to 
CD133+ human kidney cell administration in rats after cisplatin-induced AKI, and compare 
the therapeutic efficacy of the CD133+ cells with a negative control population of CD133- 
cells. The GFR is the most accurate measure of renal excretory function but classical GFR 
measurements involve the need for repeated blood and/or continuous urine sampling over a 
prolonged time period (5-24h), which is difficult to obtain in rodent models. In order to 
monitor kidney function, we used a novel transcutaneous device to determine longitudinally 
the half-life (t1/2) of fluorescein isothiocyanate (FITC)-sinistrin, a molecule that is exclusively 
filtered by the kidneys, as a measure of the GFR24-27. The device has recently been used by 
our group to monitor renal function in a mouse adriamycin model, where it was found to be a 
good predictor of histological damage28. In the current study, we measured FITC-sinistrin t1/2 
before cisplatin administration, before cell injection and at several points up to day 14 in rats 
administered with either CD133+ or CD133- human kidney cells, or saline (control group), to 
determine for each individual animal the extent by which the cell treatment affected kidney 
function.  
A further aim was to identify any association between therapeutic efficacy and the extent of 
renal engraftment. To address this question, we introduced a green fluorescent protein (GFP) 
reporter gene into the CD133+ and CD133- cells so that their location within specific organs 
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could be analysed histologically. We also labelled the cells with the lipophilic dye, PKH26, to 
investigate whether there was any propensity for this dye to separate from the GFP+ kidney 
cells and label host cells, thereby giving false positive results. 
 
MATERIALS AND METHODS  
Isolation and lentiviral transduction of human kidney cells.  
Infant renal tissue was obtained from kidneys deemed unsuitable for transplantation via UK 
National Health Service Blood and Transfusion (NHSBT). The tissue was minced in small 
pieces in sterile conditions and digested with collagenase I (1mg/mL, C0130, Sigma) for 90 
minutes at 37˚C, centrifuged and incubated with DMEM/F12 containing DNAse I (1%) 
(Sigma) for 15 minutes at room temperature. The cell suspension was filtered through a 70 
µm and a 40 µm sterile sieve and plated in the human renal progenitor cell (HRPC) medium 
previously used for fetal progenitor cells29. The medium was changed every two days until the 
cells reached 90% confluence. 
Lentiviral particles were produced as previously described30 using an unmodified eGFP 
vector (pHIV-eGFP, Addgene, 21373) with a multiplicity of infection (MOI) of 5, yielding 
>90% labelling efficiency. Typically, 2x105 cells were plated 8 hours before transduction. 
Once attached, the cells were incubated for 16 hours in complete medium containing the 
appropriate amount of lentiviral particles containing 8 µg/ml of Polybrene (Sigma, H9268). 
The medium was then appropriately discarded, and the cells were grown in normal medium.  
Details regarding cell sorting, cell characterisation and immunofluorescence protocols are 
provided in the online methods section. 
Animals 
All in vivo experiments were conducted at the University of Heidelberg in accordance with 
the German Animal Protection Law and approved by the local authority 
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(Regierungspräsidium Nordbaden, Karlsruhe, Germany, in agreement with EU directive 
2010/63/EU). 8-9 weeks old male immunodeficient athymic nude rats (Crl:NIH-Foxn1rnu, 
Charles River Laboratories) were housed in pairs in individually ventilated cages and 
acclimated for 1 week before the start of the experiments.  
Cisplatin-induced kidney injury 
Freshly prepared cisplatin solution (Sigma, dissolved in sterile 0.9% saline (AlleMan Pharma) 
was administered intraperitoneally (IP) at 7mg/100g body weight. For the two-week 
experiment, a total of twenty male immunodeficient athymic nude rats were used. Onset of 
renal damage following cisplatin administration was confirmed at day 2 via measurements of 
FITC-sinistrin (Fresenius Kabi, Linz, Austria) t1/2 as described below.  
Renal biomarker analysis 
Serum was collected from whole blood samples before the induction of damage, and then on 
days 7 and 14 after cisplatin administration via the ophthalmic venous plexus (orbital sinus), 
and stored at -20°C until use. For urine collection, the animals were housed for 16 hours in 
individual metabolic cages with free access to water and food. At the end of each collection 
period, the urine volume was recorded, and the samples were centrifuged (78g, 5 minutes) 
and immediately frozen at -20°C until analysed. Serum creatinine (sCr), serum urea and urine 
creatinine were determined using the Cobas c311 analyzer (Roche Diagnostics GmbH, 
Mannheim, Germany). Albumin levels in urine were determined by ELISA and the values 
were normalized to the amount of urinary creatinine over a 24 hour period. Assessment of 
glomerular filtration at baseline and on days 2, 7 and 14 after cisplatin administration was 
performed by administering FITC-sinistrin into the tail vein, and detecting the fluorescence 
signal transcutaneously for 90 minutes using a miniaturized device (Mannheim Pharma and 
Diagnostic, Mannheim, Germany). The FITC-sinistrin t1/2 was computed using a specifically 
designed software31.  
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Cell administration 
Before each injection, GFP-expressing CD133+ and CD133- cell populations were incubated 
with PKH26 (Sigma), following manufacturer’s instructions. Animals that displayed renal 
injury by day 2 following cisplatin administration (as indicated by the FITC-sinistrin t1/2 
measurements) were randomly assigned to three groups, two of which received either 106 
GFP-expressing CD133+ or CD133- cells in a 500 µl volume of sterile phosphate-buffered 
saline (PBS) via lateral tail vein injection; the cisplatin-injured control group received PBS 
(CD133+ group, 6 animals; CD133- group, 6 animals; cisplatin-injured control group, 7 
animals). A scheme of the experimental design is shown in Fig. 2A). On day 7, cell-treated 
animals received a second dose of either 106 GFP-expressing CD133+ or CD133- cells into the 
tail vein.  
For the biodistribution study, a total of eight male immunodeficient athymic nude rats were 
used. After assessment of cisplatin-induced renal damage on day 2, 106 CD133+ cells were 
injected into the lateral tail vein of 6 animals. 2 animals each were sacrificed at 1, 6 and 24 
hours after cell injection. Additionally, 2 uninjured control animals were sacrificed 1 hour 
after injection of saline.  
 
Morphological and histological analysis 
For the morphological and histological analysis, 4 uninjured rats were included in the study. 
Immediately after culling, kidneys and lungs were excised, fixed in 4% paraformaldehyde for 
24 hours and paraffin embedded or frozen for immunohistological analysis (see below). 3µm-
thick paraffin sections were stained with hematoxylin and eosin (H&E) or Masson’s 
Trichrome (MT). For the measurement of mean luminal area, 10 random fields of the renal 
cortex of each animal were imaged using a 20X objective. The images were transformed into 
black and white (B&W, 8 bit), and a B&W threshold was applied using Fiji software. The 
luminal areas on the edge of the image were excluded from the analysis. For measurement of 
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the fibrotic areas in MT-stained sections, 10 random fields of the renal cortex of each animal 
were imaged using a 20X objective. A colour threshold (blue) to all images was applied using 
Fiji software and the blue area was computed. Also, 5 to 7 MT images of two animals per 
group were stitched together using the ‘grid-collection stitching’ plug-in of the Fiji software. 
Immunostaining of tissue sections 
Frozen sections were blocked with 0.1% Triton-X 100 (Sigma) and 10% goat serum (Sigma) 
in PBS and incubated with anti-Calbindin (1:500, Sigma, C9848), anti-CD68 (1:500, Abcam, 
ab31630) anti-GFP (1:5000, Abcam, ab6556), anti-HLA (1:50, Santa Cruz, sc-25619), anti-
human nuclei (1:200, Millipore, MAB 1281), anti-IL10 (1:200, Abcam, ab9969), anti-
megalin (1:200, Acris antibodies, DM3613P) followed by incubation with the secondary 
antibodies Alexa Fluor® 488-coupled goat anti-rabbit IgG, Alexa Fluor® 633-coupled goat 
anti-mouse IgG1, Alexa Fluor® 647-coupled goat anti-rabbit, Alexa Fluor® 594-coupled goat 
anti-mouse IgG1 (Thermo-Fisher Scientific). Nuclei were counterstained with DAPI 
(Invitrogen). Fluorescence images were taken using a spinning disk confocal microscope 
CSU-X1 (3i Marianas), coupled with a digital camera (CMOS, Hamamatsu). The megalin 
stitched images were composed using the ‘pairwise stitching’ plug-in of the Fiji software 32.  
Statistics 
All data are presented as mean ± standard error mean (SEM). All statistical analysis was 
performed using GraphPad software, and a one-way ANOVA was used to compare three or 
more groups. The statistical significance was assumed for a p-value (p) < 0.05. 
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RESULTS   
Human kidney-derived cells express CD133 in culture 
In order to analyse the role of human kidney-derived cells in renal regeneration or repair, we 
generated primary cultures of renal cells by dissociating cortical fragments isolated from 
healthy infant renal tissue.  We analysed histological sections and primary renal cell cultures 
for expression of CD133, which has been previously described as a marker for kidney 
progenitor cells16,21,33. Immunohistological analysis of the kidney sections demonstrated 
CD133 localisation in cells of the Bowman’s capsule, and on the apical surface of scattered 
tubular cells (Fig. 1 A), similar to the pattern observed in adult human kidneys17,19,34. 
Following tissue dissociation, more than 65% of the cells in the primary cultures expressed 
CD133, as shown by immunofluorescence (Fig. 1 B) and flow cytometric analysis (Fig. 1 C). 
Since CD133+ renal progenitor cells have been reported to co-express CD2435, we verified by 
flow cytometry that all CD133+ expressed CD24; however, only 70% of CD24+ cells 
expressed CD133 (Fig. 1 D). Thus, our results show that following isolation, the majority of 
the kidney-derived cells expressed CD133 in culture.  
CD133+ and CD133- human kidney cells ameliorate renal function  
We induced kidney injury in 8-9 week old male athymic nude rats by injecting cisplatin at 
7mg /100g body weight. Animals were monitored for renal function by measuring the FITC-
sinistrin t1/2 at days 2, 7 and 14, and the serum injury markers sCr and urea at days 7 and 14. 
In 62.5% (20 out of 32) of the rats, an increase in the FITC-sinistrin t1/2 was detected at day 2 
when compared to baseline measurements before cisplatin administration. Only these animals 
were used for the subsequent study by assigning them to three groups which received on days 
2 and 7 by IV injection either (i) CD133+ passage 5 (P5) cells, (ii) CD133- P5 cells, or (iii) 
saline (Fig. 2A).  
11	
	
Prior to injection, the cells had been transduced with a pHIV-eGFP vector and sorted for 
CD133 expression using FACS (Supplemental Fig. 1A-D). Flow cytometry demonstrated 
that at passage 5, the GFP+ CD133+ population had a purity of 91.36 ± 9.17 %, and the GFP+ 
CD133- population had a purity of 92.99 ± 6.00 % (n=3) (Fig. 2B). The cell morphologies of 
the two populations after GFP-lentivirus transduction were very similar to the un-transduced 
CD133+ and CD133- cells (Supplemental Fig. 1 E). The CD133+ population appeared 
epithelial-like, whereas the CD133- population was composed of elongated mesenchymal-like 
cells. Compared with CD133+ cells, the CD133- cells expressed noticeably lower levels of the 
epithelial marker, Epcam (Supplemental Figure 2). To investigate if the CD133- cells 
resembled MSCs, which are known to reside in the kidney36, we performed flow cytometric 
analysis to determine the expression levels of key MSC markers. We found that in 
comparison with human bone marrow-derived MSCs, both the CC133+ and CD133- cells 
expressed very low levels of the MSC markers, CD90 and CD105 (Supplemental Figure 2). 
Thus, given that the CD133- cells are non-epithelial, and are also not MSCs, it is most likely 
that they are renal interstitial cells, which include various cell types, including interstitial 
fibroblasts37. Prior to administering the cells, as an additional method to track them, the cells 
were labelled  with the lipophilic fluorescent dye, PKH26, which had been used in previous 
studies17,19,21,38,39. 
Sequential measurements of the FITC-sinistrin t1/2 clearance revealed that on day 7, the FITC-
sinistrin t1/2 was significantly reduced in animals that received either CD133+ or CD133- cells, 
when compared to those of the cisplatin-injured group, indicating an improvement in renal 
function (Fig 2C, Supplemental Table 1). It is important to note that no significant 
differences in FITC-sinistrin t1/2 were observed between animals of the two cell-treated 
groups. By day 14, the FITC-sinistrin t1/2 had decreased in the cisplatin-injured animals, and 
was no longer significantly different from that of the cell-treated groups. No further decrease 
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in the FITC-sinistrin t1/2 was observed in the cell-treated groups after day 7, indicating that the 
second cell injection had no additional beneficial effects on renal function (Fig. 2C).  
In addition to the improvement in glomerular filtration function, the administration of 
CD133+ cells resulted in statistically reduced sCr (by 72.3%) and urea (by 74.2%) at day 7. In 
the CD133--treated group, sCr and urea values were also lower than in rats from the cisplatin-
injured group, though these were not statistically significant (Fig. 2D-E; Supplemental 
Table 1). By comparing the FITC-sinistrin t1/2 values at day 14 with the baseline values, it 
could be seen that renal function was not completely restored in either the CD133+ or CD133- 
treated rats (Fig. 2C). The comparison between serum creatinine baseline and d14 values also 
suggested that cell treatments failed to restore levels back to baseline (Fig. 2D), while the 
serum urea values suggested there was a complete restoration (Fig. 2E). However, given that 
both these biomarkers are less accurate indicators of renal function than FITC-sinistrin t1/2, we 
conclude that the cell therapy does not fully restore renal function.  
To further investigate the degree of tubular injury at the study end-point (day 14), kidney 
sections were stained for the PTC marker, megalin, and the collecting tubule marker, 
calbindin. No differences in the pattern of calbindin staining was observed between any of the 
groups, but megalin staining was atypical in the cisplatin-injured rats, consistent with PTC 
injury (Supplemental Figure 3 A-B). It is known that megalin plays an important role in re-
absorbing filtered albumin40. Thus, to investigate if the injured rats displayed higher levels of 
albuminuria compared with those that received cell therapy, the urinary albumin:creatine ratio 
was measured at days 2, 7 and 14. The results showed that the albumin:creatinine ratio 
increased from day 7 to day 14 in the injured rats, but was not significantly greater than 
background levels in rats that received the cell therapy (Supplemental Figure 3 C).   
Thus, our results demonstrate that CD133+ cells could ameliorate the acute phase of cisplatin-
induced renal injury in nude rats when compared to cisplatin-injured animals, as shown by the 
significant reduction in FITC-sinistrin t1/2, sCr, serum urea and urinary albumin (Fig. 2C-E 
13	
	
and Supplemental Figure 3C). Of note, CD133- cells had a similar beneficial effect on 
kidney function, since the differences in measurements of all 4 parameters between the 
CD133+ and CD133- -treated animals were not significant. 
CD133+ and CD133- human kidney cells ameliorate histological damage  
Next, we used histopathological analysis to investigate the impact of the administered cells on 
renal tissue health at day 14. In H&E-stained sections from kidneys of the cisplatin-injured 
group, abnormalities typical of acute tubular injury were observed, including cells with 
pyknotic nuclei and dilated tubules with flattened epithelia (Fig. 3A). By contrast, these 
features were rarely observed in kidneys from the cell-treated groups and uninjured control 
kidneys (Fig. 3A).  
We assessed the tubular damage by measuring the mean luminal area, which revealed that the 
tubular luminal area of cisplatin-injured rats was significantly greater than that of the cell-
treated groups and uninjured control rats (cisplatin-only: 5400µm2±739, n=7; CD133+: 
3000µm2±218 (p<0.01), n=7; CD133-: 3100µm2±301 (p<0.05), n=6; uninjured: 1350 µm±26 
(p<0.001)) (Fig. 3B).  
Previous studies have shown that by 14 days following cisplatin administration, extensive 
fibrosis is present in rat kidneys 41. To determine whether administration of the CD133+ and 
CD133- cells could ameliorate renal fibrosis, we performed Masson’s trichrome analysis. 
Despite widespread tubular dilation in the cisplatin-injured group, fibrotic lesions were 
minimal and no significant differences were observed between the cisplatin-injured and cell-
treated groups at day 14 (Fig. 3C, D, Supplemental Fig. 4). The negligible degree of renal 
fibrosis in these animals is likely due to the fact that they lack T cells, which are known to 
play a key role in the development of renal fibrosis42.  
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CD133+ and CD133- cells do not engraft in the kidneys following intravenous 
administration 
Previous studies have suggested that intravenously administered CD133+ human kidney cells 
ameliorate injury by engrafting in the kidney and generating podocytes and proximal tubule 
cells17,19. MSCs, on the other hand, become entrapped in the lung following intravenous 
administration and ameliorate renal injury via paracrine or endocrine factors12,14,43. To 
investigate whether CD133+ and CD133- human kidney cells were present in the kidneys or 
lungs following IV administration in the rat cisplatin model, tissue sections were analysed for 
the presence of GFP and PKH26 at day 14. 
PKH26 could be detected in the kidneys of rats that received human kidney cells, and was 
typically located close to tubular or interstitial cells, but there was no evidence of any GFP+ 
cells (Fig. 4B-C). Similarly, no GFP+ cells, but traces of PKH26 dye, were identified in the 
lungs of animals treated with human kidney cells (Fig. 4E-F). As expected, neither PKH26 
nor GFP+ cells were found in kidneys or lungs of cisplatin-injured animals that did not receive 
cells (Fig. 4A, D, see Supplemental Fig. 5 for a comparison between a GFP+ cell and an 
autofluorescent cell). The presence of PKH26 in the absence of GFP suggested that PKH26 
staining at day 14 was due to false positive staining of host cells. Overall, these results 
indicated that the administered cells were not detectable in kidneys or lungs by day 14. 
To demonstrate the presence of the human kidney cells and investigate their fate at earlier 
time points, CD133+ human kidney cells were IV injected into cisplatin-injured rats and tissue 
sections analysed for the presence of cells at 1, 6 and 24 hours after cell administration. Using 
GFP- and human-specific antibodies (i.e., against HLA and a human nuclear antigen), we 
could detect GFP+ human cells in sections of lungs collected one hour after cell 
administration (Fig. 5A-B). However, the presence of pyknotic nuclei and blebbing in some 
of the GFP+ cells suggested that they were undergoing cell death. In addition, we could 
identify a punctate pattern of PKH26 dye in or around the cells. In sections of lungs collected 
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six hours after cell administration, we found both fragmented and intact GFP+ cells. 
Importantly, we detected the PKH26 label not only in GFP+ cells, but also in neighbouring 
GFP- cells (Fig. 5C-C’). At the 24-hour time point, we could only identify the GFP signal in 
cell fragments close to PKH26+ puncta, but not in intact cells (Fig. 5D). By contrast, analysis 
of kidney sections at all three time points revealed only punctate PKH26 staining, but no 
GFP+ cells or fragments. HLA staining was occasionally detected in the kidney, but no human 
nuclei were observed, confirming the lack of engraftment of intact cells in this organ (Fig. 
5E-H). To investigate whether the cells had engrafted in the spleen and liver, tissue sections 
from these organs were stained for GFP and the human-specific antigens, but only 
background autofluorescence could be detected (see Supplemental Figure 6 for spleen data; 
liver data not shown). Therefore, our data demonstrate that following tail vein injection, the 
human kidney cells became entrapped in the lungs and died within 24 hours of administration. 
Importantly, our results provide no evidence of the cells engrafting in the kidneys. 
Intravenous injection of human kidney cells leads to macrophage infiltration in the 
lungs 
Dying cells and their fragments are known to be phagocytosed by resident macrophages44 and 
dendritic cells45. Furthermore, the process of macrophage-based removal of apoptotic cells 
has been shown to inhibit inflammation via anti-inflammatory cytokines46,47. To determine 
whether macrophages were recruited to the dying human cells, we performed 
immunofluorescence staining for the pan-macrophage marker CD68 on sections from lungs at 
1, 6 and 24 hours after administration of human kidney cells. We found that the CD68+ cells 
were evenly distributed across the tissue in sections of control lungs from all time points (Fig. 
6A). By contrast, at one and six hours after cell administration, CD68+ cells appeared to 
cluster closely around intact GFP+ cells and GFP+ cell fragments (Fig. 6B, B’, C). Confocal 
imaging and volume rendering of z-stacks revealed that some of the CD68+ cells also 
contained the PKH26 label (see Supplemental Video 1 and 2), suggesting that the 
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macrophages might be involved in phagocytosing the GFP+ CD133+ cell fragments. In 
sections of lungs at 24 hours after cell administration, the CD68+ cells remained in clusters 
around small GFP-labelled fragments while intact human cells were no longer present (Fig. 6 
D, D’). Analysis of expression of the anti-inflammatory cytokine IL10 in the lungs at 24 
hours showed IL10 within and surrounding CD68+ cells in close proximity to the dying 
human cells. These results suggest that IL10 may have been released by the macrophages 
following phagocytosis of the human cells (Supplemental Figure 7).  
 
DISCUSSION   
In this study we have shown that CD133+ cells isolated from human infant renal tissue could 
improve renal function and ameliorate tissue damage following intravenous administration in 
a rat cisplatin model. These findings are consistent with previous studies that showed adult 
kidney-derived CD133+ cells had beneficial effects following tail vein injection in mouse 
models of glomerular and tubular injury19,48. However, whereas these earlier studies reported 
no beneficial effects of CD133- cells, we found that in the rat cisplatin model, CD133+ and 
CD133- cells were similarly therapeutic (Table 1).  
CD133 has previously been identified as a marker for various types of stem cells18, and has 
been reported to be a progenitor cell marker in human fetal49 and adult kidneys16,17,19. In the 
fetal kidney, this was mainly based on evidence that CD133 was expressed in the metanephric 
mesenchyme49, a population of cells within the developing mammalian kidney that gives rise 
to all cell types of the nephron. However, more recent analysis has shown that CD133 is not 
co-expressed with the bona fide nephron progenitor marker, SIX2, and is instead expressed in 
differentiating cells50, suggesting that CD133 is not a progenitor marker in the fetal kidney. In 
adult human kidneys, CD133 is expressed in parietal epithelial cells17 and in a small 
population of scattered tubular epithelial cells within the proximal and distal tubules17,51,52, 
which is consistent with the staining pattern observed in infant kidneys in the current study. 
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The most compelling evidence for CD133 being a renal progenitor marker is based on studies 
showing that following IV administration into mice with renal injury, adult human kidney-
derived CD133+ cells could engraft in the kidneys and generate podocyte and proximal tubule 
cells17,19. However, this contrasts with our current study, where we found that following tail 
vein injection, infant kidney-derived CD133+ and CD133- cells did not engraft into injured 
kidneys, and instead, were entrapped in the lungs and did not survive beyond 24 hours. 
A possible explanation for these apparent differences in CD133+ biodistribution could be due 
to the fact that in the earlier studies, CD133+ cells were isolated from the ‘normal’ regions of 
adult kidneys affected by tumours. This raises the possibility that the adult CD133+ cells 
might have been renal carcinoma cells that had migrated from the primary lesion into the 
surrounding normal tissue, and perhaps as a result of their malignant phenotype, were able to 
traverse the pulmonary capillaries. It must also be considered that in the earlier studies, the 
cells were used at passage 0 (P0), whereas in the current study, the cells were used at passage 
5 (P5). Therefore, we cannot discount the possibility that P0 cells might be able to pass 
through the lung, whereas P5 cells cannot. However, it is more likely that the high level of 
renal engraftment reported in these previous studies was due to a combination of 
autofluorescence53 and false-positive staining, for it is known that the lipophilic dye, PKH26, 
that was used to monitor the fate of the CD133+ cells, can readily transfer to host cells22,54. 
Indeed, the problem with PKH26 false-positive staining was demonstrated in the current 
study, where we detected PKH26 dye in the kidneys despite the GFP-labelled CD133+ cells 
being located solely in the lungs. It is also worth noting that the high levels of renal 
engraftment reported in some earlier studies would be difficult to achieve (see Supplemental 
Table 2)17.  
The lack of renal engraftment in the current study indicates that the therapeutic effects of the 
CD133+ and CD133- cells in the rat cisplatin model are mediated by paracrine or endocrine 
factors. Our results are similar to those of a previous study by Geng and colleagues14 
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investigating the therapeutic effects of MSCs in a mouse tubular injury model, where it was 
found that following tail vein administration, cells were mainly located in the lungs and were 
not detected in the kidneys. Further experiments showed that the MSCs ameliorated renal 
injury by increasing the number of alternatively-activated (M2) macrophages14. It is well-
established that MSCs have immunomodulatory effects and ameliorate renal injury by 
paracrine mechanisms12,13, but more recently, it has been shown that the therapeutic effects of 
various other cell types, including human induced pluripotent stem cell (iPSC)-derived 
nephron progenitors, are also mediated by paracrine factors55. For instance, Toyohara and co-
workers showed that if iPSC-derived nephron progenitors were injected into the renal 
parenchyma of mice with ischemia reperfusion injury, the cells could integrate and generate 
new tubular cells, but did not ameliorate injury55. On the other hand, if the cells were injected 
under the kidney capsule, they did not integrate into the kidney, but had a significant 
therapeutic effect. Likewise, the administration of rat kidney-derived renal tubule cells into 
rats with subtotal nephrectomy reduced leucocyte infiltration and inflammation, and promoted 
repair via paracrine mechanisms56. Similar findings have been reported for other organs, such 
as the liver and heart, where it was respectively shown that the therapeutic effects of 
embryonic stem cell-derived hepatocytes and cardiac stem cells were mediated by trophic 
factors57,58.  
Our observation that the CD133+ and CD133- cells had similar therapeutic effects in the rat 
cisplatin model is interesting, especially given the differences in phenotype between the two 
cell types, with the former being predominantly epithelial cells, and the latter having a more 
mesenchymal-like morphology. An important finding from our study was that similarly to 
MSCs59, the human kidney cells died quite rapidly in the lung following intravenous 
administration and induced the infiltrating macrophages to express IL10. It is well established 
that apoptotic cells release ‘find me’ signals, such as fractalkine and lysophosphatidylcholine, 
which serve as chemo-attractants for macrophages45. Moreover, following the phagocytosis of 
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apoptotic cell debris, macrophages become polarised towards an alternatively activated (M2) 
phenotype and secrete anti-inflammatory cytokines, such as IL1060, which has been shown to 
ameliorate cisplatin-induced renal injury in rodents61. Thus, it is possible that the therapeutic 
effects of the dying human kidney cells might have been due to their ability to trigger 
macrophages to secrete IL10 (and perhaps other anti-inflammatory cytokines), which could 
stimulate renal repair by promoting an early resolution of the inflammatory response. In 
support of a role for dying cells, Thum and colleagues46 have previously hypothesised that 
immunomodulatory effects can be triggered by the apoptosis of exogenous stem cells, and 
more recently, Luk et al have shown that heat-inactivated (i.e., non-viable) MSCs can 
modulate macrophages and induce a dramatic increase in IL10 expression in mice62. 
Furthermore, dying (apoptotic) cells have also been reported to release microvesicles or 
apoptotic bodies which could potentially have immunomodulatory roles in kidney 
regeneration63. This is supported by the observation that microvesicles isolated from MSCs 
have renoprotective roles in mouse models of AKI64-66. 
Though beyond the scope of the present study, by understanding the mechanisms whereby 
dying cells modulate the behaviour of key immune effector cells and ameliorate renal injury, 
it should be possible to develop safer and more effective cell-free regenerative medicine 
therapies in the future. 
 
CONCLUSION  
Here we present data showing that cells isolated from human infant kidneys have the potential 
to ameliorate functional and histological damage in rats with cisplatin-induced kidney injury. 
Our results demonstrate that CD133 expression in the cells is not required for their beneficial 
effects. Furthermore, since the human kidney cells die in the lungs shortly after their 
administration and are not detected in the kidneys, our findings indicate that the cells exert 
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their therapeutic effects via paracrine factors, and that renal engraftment is not a prerequisite 
for ameliorating renal injury. 
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FIGURE LEGENDS 
Figure 1. Identification and isolation of a population of human kidney cells. (A) 
Representative confocal fluorescence images of human kidney cells from infant human renal 
tissue showing the expression pattern of CD133 within the Bowman’s capsule (highlighted by 
white arrows) and on the apical surface of scattered tubular cells. (B) Representative 
fluorescence images of bulk cultured cells at passage 1 after isolation, stained for CD133. 
Most of the cells appear CD133-positive. (C) FACS analysis showing the proportion of 
CD133+ and CD24+ cells within the bulk population at passage 2. The majority of the cells in 
the bulk population express CD133 (68.8% ± 9.2) and CD24 (86.10% ± 6.3). (D) 
Representative flow cytometry Dot Plot of the bulk population at passage 2 stained with 
CD133 (APC) and CD24 (FITC) antibodies. Magnification: (A-B) 400x, scale bar 50µm. 
 
Figure 2. Both CD133+ and CD133- human kidney cells can ameliorate renal function at day 
7. (A) Experimental design. (B) FACS analysis of the expression of CD133 in both CD133+ 
and CD133- populations at passage 5; mean values ± SEM of three independent sortings and 
expansions. (C) Mean FITC-sinistrin t1/2 values ± SEM. (D) Serum creatinine levels. (E) Urea 
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levels. The dotted line represents the average of the respective baseline values of all animals 
(n=20). A one-way ANOVA statistical test with Dunnet Post Hoc analysis was applied to 
each data set for each time point to compare the groups. p-values are indicated in the tables 
below the graphs. CD133+ group (n=6); CD133- group (n=6); cisplatin-injured group (n=7). 
 
Figure 3. Both CD133+ and CD133- human kidney cells ameliorate histological damage. (A) 
Representative images of H&E-stained kidney sections for each experimental group, 
including uninjured rats. The nephron tubules are noticeably damaged in the cisplatin-injured 
rats that did not receive cell therapy, but the glomeruli appear normal (see inset). 
Magnification 200x, scale bar 50µm. (B) The mean luminal area is significantly reduced in 
both cell-treated groups; CD133+, p=0.0084; CD133-, p=0.0147; one-way ANOVA statistical 
test with Dunnet Post Hoc analysis; error bars represent SEM. (C) Representative images of 
Masson’s trichrome staining of kidney sections for each experimental group, including 
uninjured rats. Magnification 100x, scale bar 50µm. (D) Quantification of the fibrotic area in 
histological kidney sections after processing of at least 10 images per animal for each group; 
one-way ANOVA statistical test with Bonferroni Post Hoc analysis; error bars represent 
SEM. Abbreviations: pn, arrowhead – Pyknotic nuclei; fe, arrows – flat epithelium; d – 
dilated tubuli. 
 
Figure 4. PKH26 dye but not GFP-positive cells are found in kidneys and lungs. Maximum 
intensity projection (MIP) confocal microscopy images of representative tissue sections of 
kidneys (A-C) and lungs (D-F). In the kidneys, green autofluorescence is observed in all 
groups (white arrows). No GFP+ cells could be detected in either the kidneys or the lungs. 
Punctate PKH26 label was found in both organs. Magnification: 400x, scale bars 100µm. 
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Figure 5. Human kidney cells are entrapped in the lungs and die within 24 hours. (A-B) 
Representative MIP confocal microscopy images of lung sections of animals at 1, 6 and 24 
hours following cell administration. One hour after injection, some GFP+ cells had apoptotic 
nuclei, indicated by the arrowheads (A). (B) To confirm the identity of the GFP+ cells, 
immunostaining was performed with the human specific antibodies, HLA and Human Nuclei-
HuNu. (C-C’) By 6 hours after injection, a few intact GFP+ cells were still present, and 
PKH26 was observed in neighbouring non-GFP host cells. (D) By 24 hours, PKH26 was 
found in a punctate pattern, near GFP-labelled cell fragments. (E-H) Representative confocal 
microscopy images showing the kidney cortex of animals sacrificed at 1 and 24 hours 
following cell administration, stained for HLA (E-F) or HuNu (G-H) and GFP. No GFP+ 
cells were detected in the kidneys at any time point. Magnification: (A-D) 1000x, (E-H) 200x, 
scale bars 50 µm unless specified. 
 
Figure 6. CD68+ phagocytic cells cluster around the human kidney cells in the lungs. (A-D) 
Representative MIP confocal microscopy images showed CD68 signal (white) in lung 
sections from control and cell-administered animals at all time points. In sections from 
animals that received human kidney cells, CD68+ cells were clustered around the GFP-
labelled cells (white arrows). Scale bar is 100µm. (B’, D’) MIP confocal microscopy images 
at higher magnification, showing GFP (green), PKH26 (red) and CD68 (white). One hour 
after administration, CD68+ cells were found clustered around the human cells in sections of 
lungs. (D’) By 24 hours, some CD68+ cells were localised around GFP+ cell fragments (white 
arrow). Magnification: (A-D) 100x; (B’-D’) 400x, scale bars 50 µm. 
 
Table 1. Summary of the therapeutic efficacy observed in both cell-treated groups compared 
with the control groups. Percentage changes apply for FITC-sinistrin t1/2, sCr and BUN at day 
7, and for albumin:creatinine ratio, histological damage and fibrosis at day 14.  
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HUMAN KIDNEY-DERIVED CELLS AMELIORATE ACUTE KIDNEY 
INJURY WITHOUT ENGRAFTING INTO  RENAL TISSUE 
Running title: human kidney cells improve AKI without engrafting 
Ilaria Santeramo1*, Zeneida Herrera Perez2*, Ana Illera1, Arthur Taylor1, Simon Kenny3, 
Patricia Murray1§, Bettina Wilm1§, Norbert Gretz2§ 
SUPPLEMENTAL DATA 
SUPPLEMENTAL	METHODS	
HUMAN	CELLS	AND	TISSUE	IMMUNOFLUORESCENCE		
Upon reception, part of the human tissue was frozen for immunhistological analysis. 6 µm-
thick sections were blocked with 0.1% Triton-X 100 (Sigma) and 10% Goat Serum (Sigma) 
in PBS and incubated with anti-CD133/1 (1: 50, Miltenyi) followed by secondary antibody 
Alexa Fluor® 488 nm goat anti-mouse IgG1 (Thermo-Fisher Scientific). Fluorescence images 
were taken using a spinning disk confocal microscope CSU-X1 (3i), coupled with a digital 
camera (CMOS, Hamamatsu). 
For the immunofluorescence experiments with cells, freshly isolated cells were plated in 8-
well chamber slides (Corning), and grown until confluent. The cells were fixed in 4% PFA, 
blocked using 2% BSA (Sigma), 0.1% Triton-X in PBS and incubated with anti-CD133/2 
(1:50, Miltenyi) followed by secondary antibody Alexa Fluor® 594-coupled goat anti-mouse 
IgG (H+L) (Thermo-Fisher Scientific). Fluorescence images were taken using an 
epifluorescence Leica DM2500 microscope coupled to a Leica DFC420C camera. 
FLOW	CYTOMETRY	AND	FACS		
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For the flow cytometry analysis of the CD133+ and CD133- (shown in Figure 1C) cells, a BD 
FACS Calibur (BD Biosciences) was used. 5x105 cells were labelled with CD133/1 APC 
(Miltenyi, 1:11), CD24 FITC (Miltenyi, 1:11), or both in 1% (v/v) FBS, 0.1% NaN3 in PBS, 
according to the manufacturer instructions. Unlabelled cells were used to set the FSC, SSC 
and the fluorescence channels correctly. For FACS, a BD FACS Aria (BD Biosciences) was 
used. Cells were labelled with CD133/1 APC (1:11) in 1% (v/v) FBS at a concentration of 5-
7.5x106 cells/ml. 5x105 cells unlabelled or labelled cells were used to set the gates. Following 
the sorting, both populations were re-analysed to define the purity of the sorting and plated. 
EXPANSION	IN	CULTURE	OF	CD133+	AND	CD133-	CELLS	AND	FLOW	CYTOMETRIC	ANALYSIS	
CD133+ and CD133- cells were isolated using flow activated cell sorting (FACS) and 
expanded in culture. A low plating density was used for both cell types (2 x 105 per 10cm2 
plate). The expression of CD133/1 APC was analysed by flow cytometry at each passage, 
using a BD FACS Calibur (BD Biosciences). In order to maintain a pure population of 
CD133- cells, magnetic activated cell sorting (MACS) was performing using CD133/1 PE 
(Miltenyi, 1:11) and Anti-PE Microbeads (Miltenyi, 40µl on LD columns).  At passage 5 a 
sample of the CD133+ and CD133- cells that were administered to the animals were analysed 
using flow cytometry. 0.5-1 x 106 cells were labelled with CD133/1 APC, CD133/2 PE, 
CD24 FITC, CD90 FITC, CD73 PE, CD105 FITC, CD44 FITC, CD326 FITC, CD324 APC 
(all from Miltenyi, 1:11) in 1% (v/v) FBS, 0.1% NaN3 in PBS, according to the 
manufacturer’s instructions. Unlabelled cells were used to set the gates for the forward scatter 
(FSC) and side scatter (SSC) and isotype specific control antibodies were used to set the gates 
for the fluorescence channels. For analysis of CD133+ and CD133- cells, antibodies were used 
in combination with CD133/1 or CD133/2. Human MSCs were from Lonza and cultured 
according to the manufacturer’s recommendations. 0.5-1 x 106 cells at passage 3 or 4 were 
labelled with CD133/1 APC, CD133/2 PE, CD24 FITC, CD90 FITC, CD73 PE, CD105 
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FITC, CD44 FITC, CD326 FITC, CD324 APC (all from Miltenyi, 1:11) in 1% (v/v) FBS, 
0.1% NaN3 in PBS, according to the manufacturer’s instructions. 
SUPPLEMENTAL FIGURES 
Supplemental Figure 1. Sorting for GFP+ CD133+ and GFP+ CD133- kidney cells. (A) Dot 
Plot showing FSC-A (Forward Scatter-Area) and SSC-A (Side Scatter-Area) used to 
discriminate healthy and damaged or dying cells in the bulk population. (B) Dot plot of SSC-
A and FSC-W (Forward Scatter-Width) used to discriminate doublets, which might represent 
a false positive signal. (C) Density plot showing the signal from the excitation of cells with 
the 488-nm laser (GFP, FITC-A, log scale) against the signal from the FL4 laser (CD133, 
APC-A, log scale). A small percentage of CD133+ cells was not efficiently transduced with 
GFP lentivirus (CD133+ 4.9% vs CD133- 1.4%). (D) Percentage of CD133-expressing cells 
after sorting into CD133+ and CD133- populations. (E) Representative images of transduced 
and un-transduced CD133+ cells and CD133- cells at passage 3. The CD133+ population 
mainly comprised epithelial cells, while the CD133- population contained mostly elongated 
mesenchymal-like cells. Magnification 100x, scale bars 100 µm.  
 
Supplemental Figure 2. (A) Flow cytometric analysis performed on CD133+ and CD133- 
cells from passage 2 (P2) to passage 6 (P6). In order to achieve a high purity of the CD133- 
population, CD133-specific MACS was used to purify the population at P3 and P4. The flow 
cytometric analysis of the cells at P5 (time-point of injection) is reported in (B). 
Characterization of the CD133+, CD133- (P5, n=2) and human MSCs (hMSCs, P3-4, n=3) for 
mesenchymal and epithelial markers using flow cytometry. (C) Table indicating average ± 
SD of all the markers analysed in each cell type. 
Supplemental Figure 3.  Absence of GFP+ cells and evidence of tubular regeneration in the 
renal cortex 14 days after cell administration. (A) Representative stitched confocal images of 
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the renal cortex of animals belonging to the four experimental groups. Kidney sections were 
stained for megalin and GFP, and the confocal images stitched to a length of 2mm. In the 
cisplatin-injured group the pattern of megalin staining in some proximal tubules was atypical 
(arrows with triple heads), likely reflecting the fact that the PTCs in these tubules were 
injured. In contrast, the sections from cell-treated rats were indistinguishable from the 
uninjured animals.  While no GFP signal was detected, unspecific green fluorescence was 
present, which was particularly strong in protein casts (*) and in cross-sections of tubuli 
(white arrows). (B) Representative confocal images of the renal cortex of animals stained for 
calbindin showed no differences between the different groups.   (C) Albumin:creatinine ratio. 
The dotted line represents the average of the albumin:creatinine baseline values of all animals 
(n=20). An ANOVA one-way statistical test with Bonferroni’s Post Hoc analysis was applied 
to each data set to compare the groups at day 14. CD133
+
 group (n=7); CD133
-
 group (n=6); 
control group (n=7). * p=0.0295; * p=0.0498 Magnification (A) 100x (B) 200x, scale bars 
100 µm. 
 
Supplemental Figure 4. Masson’s trichrome staining shows negligible levels of fibrosis in 
cell-treated animals and injured controls. Representative stitched images of Masson’s 
trichrome staining of kidney sections from animals of cisplatin-injured group, CD133+-treated 
group, CD133--treated group and uninjured group. Magnification 100x, scale bar 100µm.  
 
Supplemental Figure 5. Representative confocal MIP of the lungs of an animal sacrificed 1 
hour after injection showing a GFP+ cell (left side) and an autofluorescent cell (right). 
Magnification 630x, scale bars 10 µm. 
 
Supplemental Figure 6. Representative confocal images of the spleen of an uninjured rat 
(A), cisplatin-injured rat sacrificed 1 hour after injection of PBS (B), cisplatin-injured rat 
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sacrificed 1 hour after injection of CD133+ cells (C), stained for GFP (green) and HuNu 
(white). Background autofluorescence was present in all samples but no signal was detected 
for human nuclei. Magnification 400x, scale bar 50µm.  
 
Supplemental Figure 7. Representative confocal MIP of the lungs of animals sacrificed 1 
(B) and 24 (C) hours after injection of CD133+ cells stained for IL10 (red), CD68 (white), and 
GFP (green). At 24 hours, clusters of CD68+ were observed, with an increase in the staining 
for IL10. White arrows identify green fragments belonging to GFP+ cells. Magnification 
400x, scale bar 50 µm. 
SUPPLEMENTAL TABLES 
Supplemental table 1. Mean values ± SEM for FITC-sinistrin t1/2, serum creatinine, and urea 
for all groups at all time-points evaluated. An one-way ANOVA statistical test with 
Bonferroni Post Hoc analysis was applied to each data set to compare the values at baseline 
and at day 14. * P<0.05; ** P<0.01; *** P<0.001 one-way ANOVA with Bonferroni 
correction. 
 
Supplemental table 2. Estimation of the extent of renal engraftment of CD133+ cells reported 
in a previous studya 
 
a See Ronconi et al., where 0.75 x 105 PKH26-labelled CD133+ cells were injected into the tail vein of 
mice on the 1st and 4th day following the administration of adriamycin. On day 7, the total number of 
podocytes and proximal tubule cells (PTCs) were counted in histological sections by staining for 
podocin and LTL (Lotus tetragonolobus agglutinin). The proportion of podocin+ and LTA+ cells 
labelled with PKH26 was reported to be 11% and 7%, respectively. As indicated in the above table, 
the total number of podocytes and PTCs per mouse is estimated to be 3.6 x 105 and 12.8 x 106. Thus, 
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11% of podocytes and 7% of PTCs would be equivalent to ~0.4 x 105 and ~0.9 x 106 cells, giving a 
total cell number of 0.94 x 106, which would amount to 63% of the injected cell dose (two 
administrations of 0.75x106 cells). Even if none of the cells died, which would be unlikely, and all 
passed through the lungs into the left ventricle, an engraftment level of 63% does not seem feasible 
because the kidneys only receive 20% of the cardiac output. 
 
SUPPLEMENTAL VIDEOS 
Supplemental video 1. Volume rendering of human CD133+ cell in lung tissue 1 hour 
after cell injection.  
Volume rendering of rat lung sections show a human GFP+ CD133+ cell (green) labelled with 
PKH26 (red), surrounded by CD68+ cells (white). PKH26+ can be observed in the proximity 
1. Nicholas SB, Basgen JM, Sinha S. Using stereologic techniques for podocyte counting in the 
mouse: shifting the paradigm. Am J Nephrol. 2011;33 Suppl 1:1-7. 
2. Zhai XY, Birn H, Jensen KB, Thomsen JS, Andreasen A, Christensen EI. Digital three-
dimensional reconstruction and ultrastructure of the mouse proximal tubule. Journal of the 
American Society of Nephrology : JASN. 2003;14(3):611-619. 
3. Sakamoto H, Sado Y, Naito I, et al. Cellular and subcellular immunolocalization of ClC-5 
channel in mouse kidney: colocalization with H+-ATPase. Am J Physiol. 1999;277(6 Pt 
2):F957-965. 
4. Murawski IJ, Maina RW, Gupta IR. The relationship between nephron number, kidney size 
and body weight in two inbred mouse strains. Organogenesis. 2010;6(3):189-194. 
5. Ronconi E, Sagrinati C, Angelotti ML, et al. Regeneration of glomerular podocytes by human 
renal progenitors. Journal of the American Society of Nephrology : JASN. 2009;20(2):322-
332. 
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of the human cell, co-localizing with CD68+ cells. Imaris software was used to generate 
volume rendering, starting from a stack of confocal fluorescence images (section thickness 6 
µm). 
SUPPLEMENTAL	VIDEO	2.	VOLUME	RENDERING	OF	HUMAN	CD133+	CELL	 IN	 LUNG	TISSUE	24	
HOURS	AFTER	CELL	INJECTION.		
Volume rendering of rat lung sections show a fragment of a human GFP+CD133+ cell (green), 
surrounded by a cluster of CD68+ cells (white). PKH26+  (red) can be observed in the 
proximity of the human cell and within CD68+ cells. Imaris software was used to generate the 
volume rendering, starting from a stack of confocal fluorescence images (section thickness 6 
µm). 
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